Video
Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC
Author(s):
Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.
Related Content